The Efficacy of Nasal Steroids in Treatment of Otitis Media With Effusion: Acomparative Study

Sponsor
Muteea Mubark Salmen Bakuwiri (Other)
Overall Status
Unknown status
CT.gov ID
NCT03491098
Collaborator
(none)
60
3
21.6

Study Details

Study Description

Brief Summary

Otitis media with effusion (OME) is defined as effusion in the middle ear without signs and symptoms of an acute infection. It is a leading cause of hearing impairment in children, and its early and proper management can avoid hearing and speech impairment, which can cause developmental delay in children.Although many conditions such as enlarged adenoids, cleft palate, Down syndrome, Kartagener syndrome, and nasopharyngeal neoplasm are related to the role of eustachian tube (ET) dysfunction in the pathogenesis of OME, allergic, immunologic, and infectious factors have also been claimed. Treatment of OME is still a controversial issue, as conventional treatment approaches fail to provide satisfactory and permanent relief of otologic symptoms.There is lack of proven effectiveness of the commonly given treatments, such as antibiotics, decongestants, and antihistamines, which are potentially harmful and have disadvantages. Few in those studies,investigated topical intranasal steroid for OME treatment,and in those studies, the duration of intranasal steroid application was short and there was no hearing evaluation.

Condition or Disease Intervention/Treatment Phase
  • Drug: Mometasone Furoate spray
  • Drug: prednisolone sodium phosphate 15mg
  • Drug: hypertonic sea water solution spray
Early Phase 1

Detailed Description

The aim of this study is to assess the efficacy of nasal steroids in management of OME by comparing its results with that of oral steroids and that of nasal saline spray.

Sixty patients (4-12) years aged children with OME over a period for two months will be included in this study. Informed written consent will obtained from the parents of patient studied after explanation of the research purpose.

Patient diagnosed clinically to have OME with type B tympanogram and conductive hearing loss will be enrolled in our study.

Exclusion criteria:
  1. Patients previously managed by ventilation tube.

  2. Those who had cleft palate. The patients were divided into three equal groups. In group 1, 20 patients will be received steroids spray, for. 2 months In group 2, 20 patients will be received steroids for 1 month In group 3, 20 patients will be receive hypertonic sea water solution Otoscopic examination, basic audiological evaluation including pure tone audiometry, and immittancemetry will be performed before treatment and repeated at 3 and 6 months after treatment. The evaluation was performed using ORBITR 922 VERSION2 . Examiners will be blinded to the type of treatment.

Tympanometry results were distinguished into four grades as classified by El-Anwar et al12:

type A, normal curve (pressure 50/_99 H2O); type C1 (negative pressure _100/_199 mm H2O); type C2 (negative pressure _200/_394 mm H2O); type B (flat curve).2,3,11 The average hearing thresholds at 500 Hz and 1, 2, and 4 kHz were used in the statistical comparison.

Follow-up clinical examinations were done once per week for 3 weeks, at the end of treatment. The efficacy of nasal steroid for management of OME was compared with that of oral steroid and that of nasal sinomarin spray as placebo.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Efficacy of Nasal Steroids in Treatment of Otitis Media With Effusion: Acomparative Study
Anticipated Study Start Date :
May 15, 2018
Anticipated Primary Completion Date :
Apr 30, 2019
Anticipated Study Completion Date :
Mar 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: momestone furoate spray first group: will be given

Nasonex spray one puff in each nostril daily for 8 weeks

Drug: Mometasone Furoate spray
Mometasone Furoate spray one puff in each nostril daily for 8 weeks hypertonic sea water solution spray one puff in each nostril daily for (8) weeks.

Placebo Comparator: prednisolone sodium phosphate 15mg second group: will be given

Predsol fort tablet three times per day for 1 week then gradual withdrawal over 2 weeks

Drug: prednisolone sodium phosphate 15mg
three times per day for 1 week then gradual withdrawal over 2 weeks

Placebo Comparator: hypertonic sea water solution spray third group: will be given

Nasal spray one puff in each nostril daily for 8 weeks

Drug: hypertonic sea water solution spray
one puff in each nostril daily for 8 weeks

Outcome Measures

Primary Outcome Measures

  1. Clinical examination:Hearing loss [2 weeks evaluation for 2 months]

    Hearing loss,0=no symptoms,1= present 2 weeks ,3=present daily,4=always present,

  2. Clinical examination:Nasal obstruction [2 weeks evaluation for 2 months]

    Nasal obstruction,0=no symptoms,1= present 2 weeks ,3=present daily,4=always present,

  3. Full E.N.T history [2 weeks evaluation for 2 months]

    Snoring ,sleep apnea ,difficult suckling in infants,anterior nasal discharge and conductive hearing loss.

Eligibility Criteria

Criteria

Ages Eligible for Study:
4 Years to 12 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Sixty patients (4-12) years aged children with OME over a period for two months.
Exclusion Criteria:
  • Patients previously managed by ventilation tube.

  • Those who had cleft palate.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Muteea Mubark Salmen Bakuwiri

Investigators

  • Study Chair: Ezzat M Saleh, Professor, Assiut University
  • Study Director: Mohamed M Abd ElNaeem, doctor, Assiut University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Muteea Mubark Salmen Bakuwiri, Principal Investigator, Assiut University
ClinicalTrials.gov Identifier:
NCT03491098
Other Study ID Numbers:
  • The Efficacy of Nasal Steroids
First Posted:
Apr 9, 2018
Last Update Posted:
Apr 18, 2018
Last Verified:
Apr 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Muteea Mubark Salmen Bakuwiri, Principal Investigator, Assiut University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 18, 2018